An update on the management of hepatitis-C

Journal of the College of Physicians and Surgeons Pakistan

Volumn 13, Issue 8, 2003, Pages 477-482

  Iqbal, Muhammad ^a  

^a National University of Medical Sciences   (Pakistan)

Author keywords

Genotype; Hepatitis C; Interferon and ribavirin combination treatment; Pegylated interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; ANTIFIBROTIC AGENT; ENZYME INHIBITOR; HELICASE; LEVOVIRIN; PROTEINASE INHIBITOR; RIBAVIRIN; RIBAVIRIN DERIVATIVE; RNA POLYMERASE; THYMOSIN; UNCLASSIFIED DRUG; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; DRUG RESPONSE; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MONOTHERAPY; NEEDLESTICK INJURY; NEUTROPENIA; PATIENT COUNSELING; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; COUNSELING; HEPATITIS C; HUMANS;

EID: 0041881962     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Zuberi SJ, Seroepidemiology of HBV/HCV in Pakistan. Int Hepatol Communication 1996; 5: 19-26.
2. Seeff LB, Buskell-Bales Z, Wright EC. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-11.
3. Hari P, Gopla C, Prasad K. Mother to child HCV transmission. Lancet 2001; 357: 142-3.
4. Ogasawara S, Kage M, Kosai KI. Hepatitis C virus RNA in saliva and breast milk of hepatitis C carrier mothers. Lancet 1993; 341: 561.
5. Brackmann S, Gerritzen A, Oldenburg J. Search for intrafamilial transmission of hepatitis C virus in haemophilia patients. Blood 1993; 81: 1077-82.
6. Buscarini E, Tanzi E, Zametti A. High prevalence of antibodies to hepatitis C virus among family members of patients with anti-HCV positive chronic liver disease. Scand J Gastroenterol 1993; 28: 343-6.
7. Chutaputti A. Adverse effects and other safety aspects of hepatitis-C antivirals. J Gstroenterol Hepatol 2000; 15 (suppl): E156-63.
8. Deguzman LJ, Nieto JM, Deguman SA. Plasma hepatitis C RNA is comparable to hepatic HCV RNA when obtained while on therapy at athe end of treatment as a predictor of sustained response in patients with chronic hepatitis C. Gastroenterology 2001; A -30.
9. Orito E, Mizokami M, Mizoguchi N. Hepatitis C virus serotype II respons more favourably to interferon: a therapy. J Hepatol 1994; 21: 130-2.
10. Pozzato G, Moretti M, Franzin F. Severity of liver disease with different HCV clones. Lancet 1991; 338: 509.
11. Gordon S, Elloway R, Long J. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs intravenous drug use. Hepataology 1993; 18: 1338-43.
12. Bjoro K, Froland S, Yun Z. Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-11.
13. Nalpas B, Thiers V, Pol S. Hepatitis C viremia and anti-HCV antibodies in alcoholics. J Hepatol 1992; 14: 381-4.
14. Takase S, Tsutsumi M, Kawahara H. The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease. Hepatology 1993; 17: 9-13.
15. Martin P, Di Bisceglie AM, Kassianides C. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989; 97: 1559-61.
16. Weltman M, Brotodihardjo A, Crewe E. Co-infection with hepatitis B and C, C and D viruses results in severe chronic liver disease and responds poorly to interferon: a treatment. J Viral Hepat 1995; 2: 39-45.
17. Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
18. Poynard T. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks versus interferon alpha-2b plus placebo for 48 weeks for the treatment of chronic hepatitis-C virus. Lancet 1998; 351: 1426.
19. McHutchison JG, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis-C. N Engl J Med 1998; 339: 1485.
20. Caritters RL, Emerson SS. Therapy of hepatitis meta-analysis of interferon alpha 2b- trials. Hepatology 1997; 26(3 suppl 1): 835-85.
21. National Institute of Health, consensus development conference panel statement, management of hepatitis-C hepatology. Therapy 1997;26 (suppl.1): S2-10.
22. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.
23. Conjeevaram HS, Ganger D, Wiley TE. Race as a predictor for sustained virological response in interferon non-responders with chronic hepatitis-C: result of a randomized, placebo controlled study with high induction dose interferon alpha-2b plus ribavirin. Gastroenterology 2001; 120: A-78 (abstract #419).
24. Manns MP, McHutchison JG, Gordon SC. Peg interferon alfa-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
25. Jacobson IM, Russo MW, Brown RS. Pegylated interferon alpha -2b plus ribavirin in patients with chronic hepatitis-C: a trial in previous non-response to interferon monotherapy or combination therapy and in combination therapy relapses. Gastroentrology 2002; 122: (A-626).
26. Teuber CG, Berg T, Lafernz M. Randomized, controlled trial with interferon-alpha (interferon-alpha) combined with amantadine sulfate in primary interferon-alpha non-responsive patients with chronic hepatitis C. Program and abstracts of the 36th Annual Meeting of the European Association for the Study of the Liver; April 18-22, 2001; Prague, Czech Republic.
27. Neumann AU, Lam NP, Dahari H. Hepatitis-C viral dynamics in vivo and the antiviral efficacy of interferon-alpha. Science 1998; 282: 103-7.
28. Hermann E, Neumann AU, Schmidt JM. Hepatitis-C virus kinetics. Antivir Ther 2000; 5: 85-90.
29. Steindl-Munda PE, Jessner W, Vogel W. High dose interferon induction therapy does not improve response to combination therapy in relapsers and non-responders to previous interferon monotherapy. Program and abstract of the 36th Annual Meeting of the European Association for the Study of the liver; April 18-22, 2001; Prague, Czech Republic.
30. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
31. Kenny-Walsh E. Clinical outcomes after hepatitis-C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-33.
32. Yuki N, Hayashi N, Kamada T. HCV viraemia and liver injury in symptom-free blood donors. Lancet 1993; 342: 444.
33. Serfaty L, Aumaitre H, Chazowlleres O. Determinants of outcomes of compensated hepatitis C-virus-related cirrhosis. Hepatology 1998; 27: 1435-40.
34. Jouet P, Roudot-Thoraval F, Dhumeaux D. Comparative efficacy of interferon alpha in cirrhotic and non-cirrhotic patients with non-A non-B hepatitis. Gastroenterology 1994; 106: 686-90.
35. Kiyosawa K, Sodeyama T, Tanaku E. Hepatitis-C in hospital employees with needle stick injuries. Ann Intern Med 1991; 115: 367-9.
36. Arai Y, Noda K, Enomoto V. Prospective study of hepatitis-C virus infection after needle stick accidents. Liver 1996; 16: 331-4.
37. Center for Disease Control and Prevention. Recommendations for prevention and control of hepatitis-C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Wkly Rep 1998; 47(NO .rr-19): 1-39.
38. Alter HJ. Descartes before the horse: I clone, therefore I am: the hepatitis-C virus in current perspective. Ann Intern Med 1991; 115: 644-9.
39. Alter MJ, Margolis HS, Krawczynski J. The natural history of community-acquired hepatitis-C in the United States. N Engl J Med 1992; 327: 1899-1905.
40. Hoofnagle JH. Hepatitis-C. The clinical spectrum of disease. Hepatology 1997; 26(suppl 1); 15S-20S.
41. Alter HJ, Purcell RH, Shih J. Detection of antibody to hepatitis-C virus in prospectively followed transfusion recipients with acute chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
42. Estaban JI, Gonzalez A, Hernanedez JM. Evaluation of antibodies to hepatitis-C virus in a study of transfusion associated hepatitis. N Engl J Med 1990; 323: 1107-12.
43. Aach RD, Stevens CE, Hollinger FB. Hepatitis-C virus infection in posttransfusion hepatitis: an analysis with first- and second-generation asssays. N Engl J Med 1991; 325: 1325-9.
44. Temolada F, Casarin C, Tagger A. Antibody to hepatitis-C virus in posttransfusion hepatitis. Ann Intern Med 1991; 114: 277-81.
45. Chau KH, Dawson GJ. Mushahwar IK. IgM antibody response to hepatitis-C virus antigens in acute and chronic posttransfusion non-B hepatitis. J Virol Methods 1991; 35: 343-52.
46. Yuki N, Hayashi N, Ohkawa K. The significance of immunoglobulin M antibody response to hepatitis-C virus core protein in patients with chronic hepatitis-C. Hepatology 1995; 22: 402-6.
47. Quiroga JA, Binsbergen JV, Wang CY. Immunoglobulin M antibody to hepatitis-C virus core antigen: correlations with viral eplication, histological activity, and disease outcome. Hepatology 1995; 22: 1635-40.
48. Omata M, Yokosuks O, Takano S. Resolution of acute hepatitis-C after therapy with natural beta interferon. Lancet 1991; 338: 914-5.
49. Viladomiu L, Genesca J, Esteban JI. Interferon-alfa in acute posttransfusion hepatitis-C: a randomized controlled trial. Hepatology 1992; 15: 767-9.
50. Tassopoulos NC, Koutelou MG, Papatheodoridis G. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. Gut 1993; 34(suppl): S130-S132.
51. Alberti A, Chemello L, Belussi F. Outcome of acute hepatitis-C and role of interferon alpha therapy. In: Nishioka K, Suzuki H, Oda T, (edi). Viral hepatitis and liver disease. Tokoyo: Springer Verlag 1994: 604-6.
52. Palmovic DI, Kurelac I, Cryjakovic-Palmovic J. The treatment of acute posttransfusion hepatitis-C with recombinant interferon-alpha. Infection 22: 222-3.
53. Lampertico P, Rumi M, Romeo R. A multicenter randomized controlled trial of recombinant interferon-alpha-2b in patients with acute transfusion-associated hepatitis-C. Hepatology 1994; 19: 19-22.
54. Hwang SJ, Lee SD, Chang CY. A randomized controlled trial of recombinant interferon alfa-2b in the treatment of Chinese patients with acute post-transfusion hepatitis-C. J Hepatol 1994; 21: 831-6.
55. Jachel C, Corngerg M, Santantoniot. Treatment of acute hepatitis-C infection with intaferon alpha-2b minotherapy prevents developments of chronic HCV infections. Gastroenterology 2001: 120: A 567.
56. Consensus Conference, Treatment of hepatitis C. Masion de La, Fato (France) 2002.
57. Marcellin P, Levy S, Benhamous J. Management of the asymptomatic HCV carrier with normal ALT levels. Viral Hepat Rev 1996; 2: 277-83.
58. Nishiguchi S, Kuraoki T, Nakatani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active heptatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
59. Mazella G, Accogli E, Sottili S. Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141-7.
60. Fattovich G, Giustina G, Degos F. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in European patients with cirrhosis type C. J Hepatol 1997; 27: 201-5.
61. Booth JCL, O'Grady J, Neuberger J. On behalf of the Royal College of Physicians of London and the British Society of Gastroenterology; clinical guidelines on the management of hepatitis C. Gut 2001; 49(suppl 1):11-121.